Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
The award follows FDA review of Palvella’s annual performance progress report, which included results from the Phase 3 SELVA trial. In February 2026, Palvella announced positive topline results from the Phase 3 SELVA
Palvella got more FDA money to test a rare disease treatment. This shows the FDA thinks the medicine is worth studying further.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.